Pulmatrix, Inc. (PULM) Starts Presentation at Marcum MicroCap Conference

Pulmatrix NASDAQ: PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease  using its clinically validated, proprietary iSPERSE technology. The company’s PUR0200 is a branded generic in clinical development for chronic obstructive pulmonary disease. Pulmatrix’s proprietary product pipeline is focused on advancing treatments for rare diseases, including an inhaled anti-fungal for patients with cystic fibrosis. For more information, visit the company’s website at www.pulmatrix.com